XCUR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology...

Stats
Today's Volume	28 216.00
Average Volume	218 142
Market Cap	4.33M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $0 ) 2024-04-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0.280
ATR14	$0.00400 (0.79%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Miller Josh	Sell	46	Common Stock
2024-02-29	Dgp Co., Ltd.	Sell	3 400 000	Common Stock
2023-11-16	Miller Josh	Sell	38	Common Stock
2023-09-26	Eom Minhee	Buy	0
2023-08-21	Ko Hyuk Joon	Buy	0

INSIDER POWER
-66.27
Last 81 transactions
Buy: 16 542 799 \| Sell: 13 981 621

Exicure Inc Correlation

10 Most Positive Correlations
PAIC	0.95
SVAC	0.903
RMRM	0.869
TLGT	0.853
GAINL	0.846
ISNS	0.831
BBCP	0.804

10 Most Negative Correlations
NETE	-0.938
RAVN	-0.905
BOCH	-0.904
MMAC	-0.899
AMRB	-0.87
SHSP	-0.865

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Exicure Inc Financials

Annual	2022
Revenue:	$28.83M
Gross Profit:	$26.97M (93.56 %)
EPS:	$-0.560

FY	2022
Revenue:	$28.83M
Gross Profit:	$26.97M (93.56 %)
EPS:	$-0.560

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-22.05

FY	2020
Revenue:	$16.61M
Gross Profit:	$16.61 (0.00 %)
EPS:	$-8.49

Financial Reports:

No articles found.

Exicure Inc

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Realtime updates for Exicure Inc [XCUR]

Upcoming Earnings Alert